Disease Specific Test Reagents Clinical Trial Analysis

Summary

Global Markets Direct's "Disease Specific Test Reagents Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Disease Specific Test Reagents manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Disease Specific Test Reagents market categories - Allergy,Anaemia/ Vitamins,Rheumatoid Disease,Auto-Immune Disease
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Disease Specific Test Reagents market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Disease Specific Test Reagents Clinical Trials
  • 2.1 Disease Specific Test Reagents Clinical Trial By Equipment Type
  • 2.2 Disease Specific Test Reagents Clinical Trials By Trial Phase and Trial Status
  • 2.3 Disease Specific Test Reagents Pipeline Products By Development Stage
  • 2.4 Disease Specific Test Reagents Pipeline Products By Therapy Area
  • 2.5 Disease Specific Test Reagents Pipeline Products By News Summary
  • 2.6 Disease Specific Test Reagents EP-vCJD Assay
    • 2.6.1 Trial on Blood Test for vCJD
  • 2.7 Disease Specific Test Reagents LymPro Test
    • 2.7.1 LymPro Test - Pilot Study Preliminary Results
  • 2.8 Disease Specific Test Reagents ChemoFx Assay
    • 2.8.1 A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Incorporated Chemoresponse Assay in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
    • 2.8.2 ChemoFx Assay Results Correlate With Outcomes in Breast Cancer
  • 2.9 Disease Specific Test Reagents Systemic-Lupus Erythematosus
    • 2.9.1 The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study
  • 2.10 Disease Specific Test Reagents PreGen-Plus
    • 2.10.1 Pregen Plus For Colorectal Cancer
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Jun 01, 2009: Precision Therapeutics Presents New Data To Support Use Of ChemoFX
    • 3.1.2 Mar 31, 2009: MEC Dynamics Corp Announces FDA Approval Of Its New Avie A1c Point-Of-Care Test
    • 3.1.3 Mar 17, 2009: Quest Diagnostics Receives New York State Clinical Laboratory Approval For ClariSure Postnatal Molecular Test
    • 3.1.4 Mar 10, 2009: ArcticDx Inc. Launches Macula Risk Genetic Test For Age-Related Macular Degeneration
    • 3.1.5 Mar 03, 2009: Provista Life Sciences Announces Availability Of BT Test For Breast Cancer
    • 3.1.6 Feb 25, 2009: Adlyfe And Wyeth Jointly Develops Biomarker Assays For Treatment Of Alzheimer's Disease
    • 3.1.7 Jan 08, 2009: Quest Diagnostics Acknowledges Vitamin D Test Errors
    • 3.1.8 Dec 18, 2008: FDA Approves Beckman Coulter Anemia Test & Diagnostic Index
    • 3.1.9 Dec 16, 2008: Axis-Shield To Develop And Manufacture Active-B12 Assay For Abbott's Architect Analyser
    • 3.1.10 Oct 28, 2008: Ikonisys Receives FDA Clearance For Non-Invasive, HER-2 Breast Cancer Test
    • 3.1.11 Oct 28, 2008: Rapid Test Detects Legionnaire's Disease In 15 Minutes
    • 3.1.12 Sep 17, 2008: SQI Diagnostics Announces Positive Results Of QuantiSpot RA Microarray Consumable Test From Mt. Sinai/Cleveland Clinic External Multi-Site Validation Studies
    • 3.1.13 Sep 16, 2008: Almac Diagnostics Launches Ovarian Cancer Research Tool
    • 3.1.14 Aug 23, 2008: US College Students Needing TB Testing Now Have The Benefit Of QFT
    • 3.1.15 Aug 01, 2008: Oxford Immunotec Limited T-Spot TB Gains FDA Premarket Approval
    • 3.1.16 Jul 17, 2008: First AbD Serotec Generated HuCAL Antibodies Distributed As Part Of Clinical Diagnostic Kits For Autoimmune Diseases
    • 3.1.17 Jul 17, 2008: First AbD Serotec Generated HuCAL Antibodies Distributed As Part Of Clinical Diagnostic Kits For Autoimmune Diseases By Phadia AB: EliA
    • 3.1.18 Jul 15, 2008: Pronostics To Supply The School Of Medicine, University Of Birmingham With Next Generation Diagnostics For Autoimmune Disease: UltraPlex ANA assay
    • 3.1.19 Jul 15, 2008: Pronostics To Supply The School Of Medicine, University Of Birmingham With Next Generation Diagnostics For Autoimmune Disease: UltraPlex system
    • 3.1.20 Jun 26, 2008: Evidence Supports QFT Use In Patients With Kidney Failure
    • 3.1.21 Apr 02, 2008: Evidence Confirms QFT Superiority In Rheumatoid Arthritis Patients
    • 3.1.22 Feb 15, 2008: New Australian Blood Test Proven Six Times More Effective For Tuberculosis Control
  • 3.2 Product Approvals
    • 3.2.1 Mar 31, 2009: MEC Dynamics Corp Announces FDA Approval Of Its New Avie A1c Point-Of-Care Test
    • 3.2.2 Dec 18, 2008: FDA Approves Beckman Coulter Anemia Test & Diagnostic Index
    • 3.2.3 Oct 28, 2008: Ikonisys Receives FDA Clearance For Non-Invasive, HER-2 Breast Cancer Test
    • 3.2.4 Aug 01, 2008: Oxford Immunotec Limited T-Spot TB Gains FDA Premarket Approval
  • 3.3 Clinical Trials
    • 3.3.1 Jun 01, 2009: Precision Therapeutics Presents New Data To Support Use Of ChemoFX
    • 3.3.2 Sep 17, 2008: SQI Diagnostics Announces Positive Results Of QuantiSpot RA Microarray Consumable Test From Mt. Sinai/Cleveland Clinic External Multi-Site Validation Studies
    • 3.3.3 Aug 23, 2008: US College Students Needing TB Testing Now Have The Benefit Of QFT
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Disease Specific Test Reagents Clinical Trial By Equipment Type
  • Table 2: Disease Specific Test Reagents Clinical Trials By Trial Phase and Trial Status
  • Table 3: Disease Specific Test Reagents Pipeline Products By Development Stage
  • Table 4: Disease Specific Test Reagents Pipeline Products By Therapy Area
  • Table 5: Disease Specific Test Reagents Pipeline Products By News Summary
  • Table 6: EP-vCJD Assay - Trial on Blood Test for vCJD
  • Table 7: LymPro Test - LymPro Test - Pilot Study Preliminary Results
  • Table 8: ChemoFx Assay - A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Incorporated Chemoresponse Assay in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
  • Table 9: ChemoFx Assay - ChemoFx Assay Results Correlate With Outcomes in Breast Cancer
  • Table 10: Systemic-Lupus Erythematosus - The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study
  • Table 11: PreGen-Plus - Pregen Plus For Colorectal Cancer
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology